An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure

References

• Mozaffarian D, Benjamin EJ, Go AS, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr, et al., Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;287(12):1541–1547.
   PubMed Web of Science ®Google Scholar
• Chen HH, Anstrom KJ, Givertz MM, et al.; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18;310(23):2533–2543.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
   PubMed Web of Science ®Google Scholar
• Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–2368.
   PubMed Web of Science ®Google Scholar
• Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care. 2004;10:336–341.
   PubMedGoogle Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167.
   PubMed Web of Science ®Google Scholar
• Moe GW, Howlett J, Januzzi JL, et al. Investigators CMIMoPWCHFI-CS. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115:3103–3110.
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628–651.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Peacock WF, Phillips CO, et al. Investigators ASACa. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943–1950.
   PubMed Web of Science ®Google Scholar
• Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–1333.
   PubMed Web of Science ®Google Scholar
• Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131–138.
   PubMed Web of Science ®Google Scholar
• Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337.
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr., Sakhuja R, O’Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315–320.
   PubMedGoogle Scholar
• Knebel F, Schimke I, Pliet K, et al. NT‐ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail. 2005;5(Suppl):S38–S41.
   Google Scholar
• Logeart D, Thabut G, Jourdain P, et al. Predischarge B‐type natriuretic peptide assay for identifying patients at high risk of re‐admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641.
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, et al. N‐terminal‐pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–2174.
   PubMed Web of Science ®Google Scholar
• O’Brien R, Squire IB, Demme B, et al. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail. 2003;5:499–506.
   PubMed Web of Science ®Google Scholar
• Bayés-Genís A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail. 2005 Jun;11(5 Suppl):S3–S8.
   PubMed Web of Science ®Google Scholar
• Cohen‐Solal A, Logeart D, Huang B, et al. Lowered B‐type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol. 2009;53:2343–2348.
   PubMed Web of Science ®Google Scholar
• Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B‐type natriuretic peptide and long‐term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) linked to medicare claims. Circ Heart Fail. 2011;4:628–636.
   PubMed Web of Science ®Google Scholar
• Omar HR, Guglin M. Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission-to-discharge percentage BNP reduction. Int J Cardiol. 2016 Oct 15;221:1116–1122.
   PubMed Web of Science ®Google Scholar
• Sudharshan S, Novak E, Hock K, et al. Use of biomarkers to predict readmission for congestive heart failure. Am J Cardiol. 2017 Feb 1;119(3):445–451.
   PubMed Web of Science ®Google Scholar
• Dhaliwal AS, Deswal A, Pritchett A, et al. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009 May;15(4):293–299.
   PubMed Web of Science ®Google Scholar
• Ho SJ, Feng AN, Lee LN, et al. Predictive value of predischarge spectral tissue doppler echocardiography and n-terminal pro-B-type natriuretic peptide in patients hospitalized with acute heart failure. Echocardiography. 2011 Mar;28(3):303–310.
   PubMed Web of Science ®Google Scholar
• Dokainish H, Zoghbi WA, Lakkis NM, et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol. 2005 Apr 19;45(8):1223–1226.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004 Feb 10;109(5):594–600.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Brann A, Chang KW, et al. The co nfounding effects of non-cardiac pathologies on the interpretation of cardiac biomarkers. Curr Heart Fail Rep. 2018 Aug;15(4):239–249.
   PubMedGoogle Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al., PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019 Feb 7;380(6):539–548.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Daniels LB, Anand IS, et al. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. Postgrad Med. 2018 Apr;130(3):299–307.
   PubMed Web of Science ®Google Scholar
• Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017 Aug 22;318(8):713–720.
   PubMed Web of Science ®Google Scholar
• Stienen S, Salah K, Moons AH, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during Hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation. 2018 Apr 17;137(16):1671–1683.
   PubMed Web of Science ®Google Scholar
• De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev. 2015;26:615–623. Elsevier Ltd.
   PubMed Web of Science ®Google Scholar
• Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–840.
   PubMed Web of Science ®Google Scholar
• Tseng CCS, Huibers MMH, van Kuik J, et al. The Interleukin-33 / ST2 pathway is expressed in the failing Human Heart and Associated with pro-fibrotic remodeling of the myocardium. J of Cardiovasc Trans Res. 2017;11:15–21.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–2966.
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig. 2007;117:1538–1549.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Di Somma S. Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). Eur Heart J. 2017;38:2325–2332.
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circulation. 2009;2:684–691.
   PubMedGoogle Scholar
• Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea. Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. J Am Coll Cardiol. 2007;50:607–613.
   PubMed Web of Science ®Google Scholar
• Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circulation. 2009;2:311–319.
   PubMed Web of Science ®Google Scholar
• Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of Tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 2017;5:287–296.
   PubMed Web of Science ®Google Scholar
• Lassus J, Gayat E, Mueller C, et al. GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013 Oct 3;168(3):2186–2194.
   PubMed Web of Science ®Google Scholar
• Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008 Nov;14(9):732–738.
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology (Switzerland). 2012;122:158–166.
   PubMed Web of Science ®Google Scholar
• Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail. 2013 Dec;19(12):821–828.
   PubMed Web of Science ®Google Scholar
• van Vark LC, Lesman-Leegte I, Baart SJ, et al. Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol. 2017 Nov 7; 70(19):2378–2388.
   PubMed Web of Science ®Google Scholar
• Jaffe AS. Third universal definition of myocardial infarction. Clin Biochem. 2013;46:1–4.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services F and DA: 510 (k) Summary, Elecsys Troponin T Gen 5 STAT. 2017.
   Google Scholar
• Peacock WFI, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–2126.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008;101:231–237.
   PubMed Web of Science ®Google Scholar
• Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10:772–779.
   PubMed Web of Science ®Google Scholar
• Perna ER, Macín SM, Cimbaro, et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int J Cardiol. 2005 Mar 18;99(2):253–261.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Casas T, Ordonez-Llanos J, et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J. 2012 Jun;163(6):1002–1010.
   PubMed Web of Science ®Google Scholar
• Parissis JT, Papadakis J, Kadoglou NP, et al. Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels. Int J Cardiol. 2013 Oct 9;168(4):3609–3612.
   PubMed Web of Science ®Google Scholar
• Pang PS, Teerlink JR, Voors AA, et al. Use of high-sensitivity Troponin T to identify patients with acute heart failure at lower risk for adverse outcomes: an Exploratory Analysis From the RELAX-AHF trial. JACC Heart Fail. 2016 Jul;4(7):591–599.
   PubMed Web of Science ®Google Scholar
• Xue Y, Clopton P, Peacock WF, et al. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011 Jan;13(1):37–42.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011 Jul;13(7):718–725.
   PubMed Web of Science ®Google Scholar
• Liquori ME, Christenson RH, Collinson PO, et al. Cardiac biomarkers in heart failure. Clin Biochem. 2014;47(6):327–337.
   PubMed Web of Science ®Google Scholar
• Sharma UC. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–3128.
   PubMed Web of Science ®Google Scholar
• van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, Galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–1224.
   PubMed Web of Science ®Google Scholar
• Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12(8):826–832.
   PubMed Web of Science ®Google Scholar
• Lok DJA, Van Der Meer P, de la Porte PWB-A, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323–328.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Lok DJA, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–68.
   PubMed Web of Science ®Google Scholar
• Coburn E, Frishman W. Comprehensive review of the prognostic value of galectin-3 in heart failure. Cardiol Rev. 2014 Jul-Aug;22(4):171–175.
   PubMed Web of Science ®Google Scholar
• Srivatsan V, George M, Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur J Prev Cardiol. 2015 Sep;22(9):1096–1110.
   PubMed Web of Science ®Google Scholar
• Yanagawa B, Nagaya N. Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids. 2007;32(1):157–164.
   PubMed Web of Science ®Google Scholar
• Miyatake K, Sakamaki KK, Oya H, et al. Congestive heart failure hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498–503.
   PubMed Web of Science ®Google Scholar
• Daggubati S, Parks JR, Overton RM, et al. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res. 1997 Nov;36(2):246–255.
   PubMed Web of Science ®Google Scholar
• Jougasaki M, Stevens TL, Borgeson DD, et al. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997 Oct;273(4 Pt 2):R1392–R1399.
   PubMedGoogle Scholar
• van Kimmenade RRJ, Januzzi JL. Emerging biomarkers in heart failure. Clin Chem. 2012;58(1):127–138.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2011 Aug 30;58(10):1057–1067.
   PubMed Web of Science ®Google Scholar
• Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012 Sep;33(17):2197–2205.
   PubMed Web of Science ®Google Scholar
• Morbach C, Marx A, Kaspar M, et al.; INH Study Group and the Competence Network Heart Failure. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. Eur J Heart Fail. 2017 Sep; 19(9):1166–1175.
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Struck J, Jochberger S, et al. C opeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43–49.
   PubMed Web of Science ®Google Scholar
• Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med. 2006;119(7):S47–S53.
   PubMedGoogle Scholar
• Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112–119.
   PubMed Web of Science ®Google Scholar
• Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) Study. Circ Hear Fail. 2011;4(5):613–620.
   PubMed Web of Science ®Google Scholar
• Peacock WF, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011 Sep;18(9):947–958.
   PubMed Web of Science ®Google Scholar
• Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of b-type natriuretic peptide, mid-regional pro-a-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13(1):42–49.
   PubMed Web of Science ®Google Scholar
• Alehagen U, Dahlström U, Rehfeld JF, et al. Association of copeptin and N-Terminal proBNP Concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011;305(20):2088.
   PubMed Web of Science ®Google Scholar
• Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006;36(11):771–778.
   PubMed Web of Science ®Google Scholar
• Lassus J, Harjola V, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28:1841–1847.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Dupont M, Hernandez AF, et al. Comparative assessment of short-term adverse events in acute heart failure with Cystatin C and other estimates of renal function. JACC Hear Fail. 2015;3(1):40–49.
   PubMed Web of Science ®Google Scholar
• Inazumi H, Koyama S, Tanada Y, et al. Prognostic significance of changes in cystatin C during treatment of acute cardiac decompensation. J Cardiol. 2016;67(1):98–103.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Jackson K, Rao VS, et al. Worsening renal function in patients with acute heart failure undergoing aggressive. Circulation. 2018;137:2016–2028.
   PubMed Web of Science ®Google Scholar
• Bolignano D, Donato V, Coppolino G, et al. Neutrophil Gelatinase–Associated Lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595–605.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase- associated lipocalin in patients with acute heart failure : the NGAL evaluation along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. 2011;13(8):846–851.
   Google Scholar
• Alvelos M, Lourenço P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2013;165(1):51–55.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Wettersten N, Van VDJ, et al. Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations. 2016; 68(13):1420–1431.
   Google Scholar